HELLS Serves As a Poor Prognostic Biomarker and Its Downregulation

Total Page:16

File Type:pdf, Size:1020Kb

HELLS Serves As a Poor Prognostic Biomarker and Its Downregulation Wang et al. BMC Med Genomics (2021) 14:189 https://doi.org/10.1186/s12920-021-01043-5 RESEARCH Open Access HELLS serves as a poor prognostic biomarker and its downregulation reserves the malignant phenotype in pancreatic cancer Feng‑Jiao Wang1,2†, Yan‑Hua Jing1,2†, Chien‑Shan Cheng1,2, Zhang‑Qi Cao1,2, Ju‑Ying Jiao1,2 and Zhen Chen1,2* Abstract Background: SMARCAs, belonged to SWI/SNF2 subfamilies, are critical to cellular processes due to their modulation of chromatin remodeling processes. Although SMARCAs are implicated in the tumor progression of various cancer types, our understanding of how those members afect pancreatic carcinogenesis is quite limited and improving this requires bioinformatics analysis and biology approaches. Methods: To address this issue, we investigated the transcriptional and survival data of SMARCAs in patients with pancreatic cancer using ONCOMINE, GEPIA, Human Protein Atlas, and Kaplan–Meier plotter. We further verifed the efect of signifcant biomarker on pancreatic cancer in vitro through functional experiment. Results: The Kaplan–Meier curve and log‑rank test analyses showed a positive correlation between SMARCA1/2/3/ SMARCAD1 and patients’ overall survival (OS). On the other hand, mRNA expression of SMARCA6 (also known as HELLS) showed a negative correlation with OS. Meanwhile, no signifcant correlation was found between SMARCA4/5/SMARCAL1 and tumor stages and OS. The knockdown of HELLS impaired the colony formation ability, and inhibited pancreatic cancer cell proliferation by arresting cells at S phase. Conclusions: Data mining analysis and cell function research demonstrated that HELLS played oncogenic roles in the development and progression of pancreatic cancer, and serve as a poor prognostic biomarker for pancreatic can‑ cer. Our work laid a foundation for further clinical applications of HELLS in pancreatic cancer. Keywords: SMARCA , HELLS, Pancreatic cancer, Prognostic value, Data mining analysis Introduction excessive deleterious mutations, and an overall frequency Te switch/sucrose nonfermenting complex (SWI/SNF) approaching TP53 mutations [2]. Recent studies inves- is an ATPase-dependent multisubunit complex modulat- tigated the crucial implication of the SWI/SNF protein ing gene expression involved in chromatin remodeling complex in the initiation and dediferentiation of various and transcriptional regulation [1]. Te whole-exome of neoplasms, which might attribute to its regulation of sequencing data, including 18 neoplastic entities diferentiation and cell proliferation through their enrich- from 24 published studies, showed widespread SWI/ ment promoters and enhancers active genes [3]. SNF mutations among diverse human cancers (20%), Several SWI/SNF2 family members are known by a SMARCA (SWI/SNF-related Matrix-associated, Actin- dependent Regulator Chromatin Group A) class or chro- *Correspondence: [email protected] †Feng‑Jiao Wang and Yan‑Hua Jing have contributed equally to this article matin subgroup remodeler. SMARCA class of chromatin 1 Department of Integrative Oncology, Fudan University Shanghai Cancer remodeling genes (SMARCAs) play a crucial role in chro- Center, 270 Dong An Road, Shanghai 200032, China matin remodeling, especially in double-strand damage Full list of author information is available at the end of the article © The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco mmons. org/ publi cdoma in/ zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Wang et al. BMC Med Genomics (2021) 14:189 Page 2 of 13 repair [4]. SMARCAs are further made up of SMARCA1, validated by Kaplan–Meier survival curves with a hazard SMARCA2, SMARCA3, SMARCA4, SMARCA5, ratio (HR) with 95% confdence intervals (CIs). A log- HELLS, SMARCAD1, and SMARCAL1 [5]. Previous rank P value < 0.05 was considered statically signifcant. studies purposed the SMARCA family members’ carci- nogenic role in several undiferentiated and diferenti- Immunohistochemistry staining ated cancers, including lung cancer and renal cell cancer Te Human Protein Atlas (HPA) (https:// www. prote inatl [4]. However, the expression patterns and the exact roles as. org/) is a website that aims to map human proteins in of SMARCAs in pancreatic cancer remained unclear. In cells, tissues, and organs by utilizing various omics tech- this study, the protein and mRNA expression, prognos- nologies that contain immunohistochemistry-based pro- tic values, and potential functions of diferent SMARCA tein expression, mass spectrometry-based proteomics, family members in pancreatic cancer were systematically transcriptomics, and systems biology [11]. In this study, explored. diferent SMARCA members’ expression between pan- creatic cancer and normal tissues was verifed by immu- Materials and methods nohistochemistry image. ONCOMINE database analysis ONCOMINE database (www. oncom ine. org) is a publicly Functional enrichment analysis accessible online cancer microarray database to collect, Metascape (http:// metas cape. org) is a free gene-list anal- standardize, analyze, and deliver cancer transcriptome ysis tool for gene annotation and analysis and an auto- data to the biomedical research community [6]. Te mated meta-analysis tool to understand common and expression levels of SMARCA gene family members in unique pathways within a group of orthogonal target-dis- diferent types of cancer tissues and their adjacent nor- covery studies [12]. In this study, the neighboring genes mal samples were identifed using ONCOMINE data- based on TCGA and GTEx expression datasets with sim- base. Te diferences were compared by students’ t-test. ilar expression pattern with SMARCA family members Te threshold was restricted as follows: P value: 0.01, fold were detected using GEPIA, respectively. Te selected change: 2, gene rank: 10%, data type: mRNA. correlate genes were further used to conduct pathway and process enrichment analysis by Metascape. For this, GEPIA dataset analysis the Gene Ontology (GO) enrichment analysis, includ- Gene Expression Profling Interactive Analysis (GEPIA) ing biological processes (BP), cellular components (CC), (http:// gepia2. cancer- pku. cn/) is a developed interactive and molecular functions (MF) were used for predicting web server for estimating the RNA sequencing expres- the functional roles of SMARCAs mutations and similar sion data, based on 9,736 tumors and 8,587 normal genes associated with SMARCAs mutations. Kyoto Ency- samples from the Cancer Genome Atlas (TCGA) and clopedia of Genes and Genomes pathways (KEGG) ana- Genotype-Tissue Expression (GTEx) dataset projects. lyzed the SMARCA family members-related pathways Te UCSC Xena project (http:// xena. ucsc. edu/) has and closely related neighbor genes of SMARCAs muta- recomputed all raw RNA-Seq data based on a standard tions. A P value cut-of < 0.01, a minimum overlap of 3, processing pipeline, thus minimizing diferences from and a minimum enrichment factor of 1.5 were considered distinct sources and making such data more compatible. as statistically signifcant. In addition, GEPIA provides essential interactive and customizable functions, including diferential expression Western blotting analysis, profling plotting, patient survival analysis, simi- Cells were collected and lysed in cold RIPA bufer sup- lar gene detection, correlation analysis, and dimensional- plemented with phenylmethanesulfonyl fuoride (PMSF; ity reduction analysis [7]. Beyotime, China) and centrifuged at 14,000 rpm and 4 °C for 15 min. Total protein concentrations were deter- Kaplan–Meier plotter mined with a BCA protein assay kit (Beyotime, China). Te prognostic value of mRNA expression of SMARCAs Equal amounts of denatured protein samples were sepa- in pancreatic cancers was evaluated using an open online rated by electrophoresis using 10% SDS-PAGE gel fast database, Kaplan–Meier Plotter (http:// kmplot. com/ preparation kits (Epizyme, China), and then transferred analy sis/). Tis database provided gene expression data onto 0.45 μm polyvinylidene difuoride (PVDF; Millipore, and survival information of patients with liver cancer and USA) membranes. Subsequently, the membranes were many other cancer types, such as breast cancer, ovarian blocked with 5% BSA diluted in Tris-bufered saline with cancer, lung cancer, and gastric cancer [8–10]. Patients 0.1% Tween-20 (TBST) at room temperature. Ten, the were divided into high and low expression groups PVDF membranes were incubated with primary anti- according to the median values of mRNA expression and bodies against β-actin (1:1000; Proteintech) and HELLS Wang et al. BMC Med Genomics (2021) 14:189
Recommended publications
  • SMARCA1 Antibody A
    Revision 1 C 0 2 - t SMARCA1 Antibody a e r o t S Orders: 877-616-CELL (2355) [email protected] Support: 877-678-TECH (8324) 0 5 Web: [email protected] 4 www.cellsignal.com 9 # 3 Trask Lane Danvers Massachusetts 01923 USA For Research Use Only. Not For Use In Diagnostic Procedures. Applications: Reactivity: Sensitivity: MW (kDa): Source: UniProt ID: Entrez-Gene Id: WB, IP H Endogenous 130 Rabbit P28370 6594 Product Usage Information 5. Ho, L. and Crabtree, G.R. (2010) Nature 463, 474-84. 6. Landry, J.W. et al. (2011) Genes Dev 25, 275-86. Application Dilution 7. Landry, J. et al. (2008) PLoS Genet 4, e1000241. Western Blotting 1:1000 Immunoprecipitation 1:50 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody. Specificity / Sensitivity SMARCA1 Antibody recognizes endogenous levels of total SMARCA1 protein. Species Reactivity: Human Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human SMARCA1 protein. Antibodies are purified by protein A and peptide affinity chromatography. Background SMARCA1 (SNF2L) is one of the two orthologs of the ISWI (imitation switch) ATPases encoded by the mammalian genome (1). The ISWI chromatin remodeling complexes were first identified in Drosophila and have been shown to remodel and alter nucleosome spacing in vitro (2). SMARCA1 is the catalytic subunit of the nucleosome remodeling factor (NURF) and CECR2-containing remodeling factor (CERF) complexes (3-5).
    [Show full text]
  • Monoclonal Antibody to SMARCA1
    AM50455PU-N OriGene Technologies Inc. OriGene EU Acris Antibodies GmbH 9620 Medical Center Drive, Ste 200 Schillerstr. 5 Rockville, MD 20850 32052 Herford UNITED STATES GERMANY Phone: +1-888-267-4436 Phone: +49-5221-34606-0 Fax: +1-301-340-8606 Fax: +49-5221-34606-11 [email protected] [email protected] Monoclonal Antibody to SMARCA1 - Purified Alternate names: ATP-dependent helicase SMARCA1, Nucleosome-remodeling factor subunit SNF2L, Probable global transcription activator SNF2L1, SNF2L, SNF2L1, SWI/SNF-related matrix- associated actin-dependent regulator of chromatin subfamily A member 1 Catalog No.: AM50455PU-N Quantity: 0.1 mg Concentration: lot-specific Background: Nucleosome-remodeling factor subunit SNF2L, also known as SWI/SNF-related matrix- associated actin-dependent regulator of chromatin subfamily A member 1 (SMARCA1), is the energy-transducing component of NURF (nucleosome-remodeling factor) and CERF (CECR2-containing-remodeling factor) complexes. These complexes facilitate the disruption of chromatin structure in an ATP-dependent manner. SNF2L potentiates neurite outgrowth, and may be involved in brain development by regulating En-1 and En-2 expression as well as in the development of luteal cells. Uniprot ID: P28370 NCBI: NP_003060.2 GeneID: 6594 Host / Isotype: Rat / IgG2b Clone: SNF 2C4 Immunogen: GST-tagged recombinant protein corresponding to human SNF2L. Format: State: Liquid purified Ig fraction Purification: Protein G Chromatography Buffer System: 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide. Applications: Immunohistochemistry: A representative lot was used by an an independent laboratory to detect SNF2L in certain, normal human organ tissues. (Eckey, M., et al.
    [Show full text]
  • SMARCA1 (D4Q7V) Rabbit
    SMARCA1 (D4Q7V) Rabbit mAb Store at -20°C 3 n 100 µl Orders n 877-616-CELL (2355) (10 western blots) [email protected] Support n 877-678-TECH (8324) [email protected] Web n www.cellsignal.com New 03/13 #12483 For Research Use Only. Not For Use In Diagnostic Procedures. Entrez-Gene ID #6594 Swiss-Prot Acc. #P28370 Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 Applications Species Cross-Reactivity* Molecular Wt. Isotype mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% W, IP H, Mk 130 kDa Rabbit IgG** sodium azide. Store at –20°C. Do not aliquot the antibody. Endogenous *Species cross-reactivity is determined by western blot. Background: SMARCA1 (SNF2L) is one of the two ortho- ** Anti-rabbit secondary antibodies must be used to logs of the ISWI (imitation switch) ATPases encoded by the detect this antibody. kDa LN18 SW620 HeLa HT-29 Saos-2 OVCAR8COS-7 mammalian genome (1). The ISWI chromatin remodeling Recommended Antibody Dilutions: complexes were first identified in Drosophila and have been 200 140 Western blotting 1:1000 shown to remodel and alter nucleosome spacing in vitro (2). SMARCA1 100 Immunoprecipitation 1:100 SMARCA1 is the catalytic subunit of the nucleosome re- 80 modeling factor (NURF) and CECR2-containing remodeling For product specific protocols please see the web page 60 factor (CERF) complexes (3-5). The NURF complex plays an 50 for this product at www.cellsignal.com. important role in neuronal physiology by promoting neurite 40 Please visit www.cellsignal.com for a complete listing outgrowth and regulation of Engrailed homeotic genes that 30 of recommended complementary products.
    [Show full text]
  • Contribution of Multiple Inherited Variants to Autism Spectrum Disorder (ASD) in a Family with 3 Affected Siblings
    G C A T T A C G G C A T genes Article Contribution of Multiple Inherited Variants to Autism Spectrum Disorder (ASD) in a Family with 3 Affected Siblings Jasleen Dhaliwal 1 , Ying Qiao 1,2, Kristina Calli 1,2, Sally Martell 1,2, Simone Race 3,4,5, Chieko Chijiwa 1,5, Armansa Glodjo 3,5, Steven Jones 1,6 , Evica Rajcan-Separovic 2,7, Stephen W. Scherer 4 and Suzanne Lewis 1,2,5,* 1 Department of Medical Genetics, University of British Columbia (UBC), Vancouver, BC V6H 3N1, Canada; [email protected] (J.D.); [email protected] (Y.Q.); [email protected] (K.C.); [email protected] (S.M.); [email protected] (C.C.); [email protected] (S.J.) 2 BC Children’s Hospital, Vancouver, BC V5Z 4H4, Canada; [email protected] 3 Department of Pediatrics, University of British Columbia (UBC), Vancouver, BC V6T 1Z7, Canada; [email protected] (S.R.); [email protected] (A.G.) 4 The Centre for Applied Genomics and McLaughlin Centre, Hospital for Sick Children and University of Toronto, Toronto, ON M5G 0A4, Canada; [email protected] 5 BC Children’s and Women’s Health Center, Vancouver, BC V6H 3N1, Canada 6 Michael Smith Genome Sciences Centre, Vancouver, BC V5Z 4S6, Canada 7 Department of Pathology and Laboratory Medicine, University of British Columbia (UBC), Vancouver, BC V6T 1Z7, Canada * Correspondence: [email protected] Abstract: Autism Spectrum Disorder (ASD) is the most common neurodevelopmental disorder in Citation: Dhaliwal, J.; Qiao, Y.; Calli, children and shows high heritability.
    [Show full text]
  • Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) Beyond SMARCA4 Mutations: a Comprehensive Genomic Analysis
    cells Article Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond SMARCA4 Mutations: A Comprehensive Genomic Analysis Aurélie Auguste 1,Félix Blanc-Durand 2 , Marc Deloger 3 , Audrey Le Formal 1, Rohan Bareja 4,5, David C. Wilkes 4 , Catherine Richon 6,Béatrice Brunn 2, Olivier Caron 6, Mojgan Devouassoux-Shisheboran 7,Sébastien Gouy 2, Philippe Morice 2, Enrica Bentivegna 2, Andrea Sboner 4,5,8, Olivier Elemento 4,8, Mark A. Rubin 9 , Patricia Pautier 2, Catherine Genestie 10, Joanna Cyrta 4,9,11 and Alexandra Leary 1,2,* 1 Medical Oncologist, Gynecology Unit, Lead Translational Research Team, INSERM U981, Gustave Roussy, 94805 Villejuif, France; [email protected] (A.A.); [email protected] (A.L.F.) 2 Gynecological Unit, Department of Medicine, Gustave Roussy, 94805 Villejuif, France; [email protected] (F.B.-D.); [email protected] (B.B.); [email protected] (S.G.); [email protected] (P.M.); [email protected] (E.B.); [email protected] (P.P.) 3 Bioinformatics Core Facility, Gustave Roussy Cancer Center, UMS CNRS 3655/INSERM 23 AMMICA, 94805 Villejuif, France; [email protected] 4 Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10001, USA; [email protected] (R.B.); [email protected] (D.C.W.); [email protected] (A.S.); [email protected] (O.E.); [email protected] (J.C.) 5 Institute for Computational Biomedicine, Weill Cornell
    [Show full text]
  • Frequent Loss of Heterozygosity Targeting the Inactive X Chromosome in Melanoma
    6476 Vol. 9, 6476–6482, December 15, 2003 Clinical Cancer Research Frequent Loss of Heterozygosity Targeting the Inactive X Chromosome in Melanoma James O. Indsto,1 Najah T. Nassif,2 INTRODUCTION Richard F. Kefford,1 and Graham J. Mann1 Chromosomal deletions and amplification events are fre- 1Westmead Institute for Cancer Research, University of Sydney at quent in advanced neoplasms and provide evidence for the Westmead Millennium Institute, Westmead, New South Wales, existence and location of putative tumor suppressor genes Australia, and 2Department of Cell and Molecular Biology, University (TSGs) and oncogenes. In melanoma, 9p and 10q deletions are of Technology, Sydney, New South Wales, Australia most frequent, and losses on 6q, 11q, 1p, 15p, 17q, and 18q are also frequently found (1, 2). However, no studies have focused on the X chromosome. In the human female, random inactiva- ABSTRACT tion of one copy of an X chromosome by hypermethylation is an After previous preliminary observations of paradoxical early event in embryogenesis, resulting in most tissues being a deletion events affecting the inactive X chromosome in mel- mosaic in terms of X inactivation status. Neoplasms, being anoma, we have surveyed the X chromosome for deletions clonal expansions of single precursor cells, usually share a using 23 polymorphic microsatellite markers in 28 inform- common X inactivation status. This can be conveniently assayed ative (female XX) metastatic melanomas. Ten tumors (36%) using the methylation-sensitive restriction enzyme HpaII, which showed at least one loss of heterozygosity (LOH) event, and has a recognition site within the highly polymorphic exon 1 in two cases an entire chromosome showed LOH at all CAG repeat (ARTR) in the androgen receptor (AR) gene.
    [Show full text]
  • The H3K9 Methylation Writer SETDB1 and Its Reader MPP8 Cooperate to Silence Satellite DNA Repeats in Mouse Embryonic Stem Cells
    G C A T T A C G G C A T genes Article The H3K9 Methylation Writer SETDB1 and Its Reader MPP8 Cooperate to Silence Satellite DNA Repeats in Mouse Embryonic Stem Cells 1,2,3,4 1 1, 1 Paola Cruz-Tapias , Philippe Robin , Julien Pontis y, Laurence Del Maestro and Slimane Ait-Si-Ali 1,* 1 Epigenetics and Cell Fate (EDC), Centre National de la Recherche Scientifique (CNRS), Université de Paris, Université Paris Diderot, F-75013 Paris, France; [email protected] (P.C.-T.); [email protected] (P.R.); julien.pontis@epfl.ch (J.P.); [email protected] (L.D.M.) 2 Faculty of Natural Sciences and Mathematics, Universidad del Rosario, Bogotá 111221, Colombia 3 School of Medicine and Health Sciences, Universidad del Rosario, Bogotá 111221, Colombia 4 Doctoral Program in Biomedical and Biological Sciences, Universidad del Rosario, Bogotá 111221, Colombia * Correspondence: [email protected]; Tel.: +33-(0)1-5727-8919 Current: Ecole Polytechnique Fédérale de Lausanne (EPFL), SV LVG Station 19, 1015 Lausanne, Switzerland. y Received: 25 August 2019; Accepted: 24 September 2019; Published: 25 September 2019 Abstract: SETDB1 (SET Domain Bifurcated histone lysine methyltransferase 1) is a key lysine methyltransferase (KMT) required in embryonic stem cells (ESCs), where it silences transposable elements and DNA repeats via histone H3 lysine 9 tri-methylation (H3K9me3), independently of DNA methylation. The H3K9 methylation reader M-Phase Phosphoprotein 8 (MPP8) is highly expressed in ESCs and germline cells. Although evidence of a cooperation between H3K9 KMTs and MPP8 in committed cells has emerged, the interplay between H3K9 methylation writers and MPP8 in ESCs remains elusive.
    [Show full text]
  • Role and Regulation of the P53-Homolog P73 in the Transformation of Normal Human Fibroblasts
    Role and regulation of the p53-homolog p73 in the transformation of normal human fibroblasts Dissertation zur Erlangung des naturwissenschaftlichen Doktorgrades der Bayerischen Julius-Maximilians-Universität Würzburg vorgelegt von Lars Hofmann aus Aschaffenburg Würzburg 2007 Eingereicht am Mitglieder der Promotionskommission: Vorsitzender: Prof. Dr. Dr. Martin J. Müller Gutachter: Prof. Dr. Michael P. Schön Gutachter : Prof. Dr. Georg Krohne Tag des Promotionskolloquiums: Doktorurkunde ausgehändigt am Erklärung Hiermit erkläre ich, dass ich die vorliegende Arbeit selbständig angefertigt und keine anderen als die angegebenen Hilfsmittel und Quellen verwendet habe. Diese Arbeit wurde weder in gleicher noch in ähnlicher Form in einem anderen Prüfungsverfahren vorgelegt. Ich habe früher, außer den mit dem Zulassungsgesuch urkundlichen Graden, keine weiteren akademischen Grade erworben und zu erwerben gesucht. Würzburg, Lars Hofmann Content SUMMARY ................................................................................................................ IV ZUSAMMENFASSUNG ............................................................................................. V 1. INTRODUCTION ................................................................................................. 1 1.1. Molecular basics of cancer .......................................................................................... 1 1.2. Early research on tumorigenesis ................................................................................. 3 1.3. Developing
    [Show full text]
  • Multiple Epigenetic Modifiers Induce Aggressive Viral Extinction
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Cell Stem Cell Article Multiple Epigenetic Modifiers Induce Aggressive Viral Extinction in Extraembryonic Endoderm Stem Cells Michael C. Golding,1,2,3,4 Liyue Zhang,3,5 and Mellissa R.W. Mann1,2,3,5,* 1Department of Obstetrics & Gynecology 2Department of Biochemistry University of Western Ontario, Schulich School of Medicine and Dentistry, London, Ontario N6A 4V2, Canada 3Children’s Health Research Institute, London, Ontario N6C 2V5, Canada 4Department of Veterinary Physiology, College of Veterinary Medicine, Texas A&M University, College Station, TX 77843, USA 5Lawson Health Research Institute, London, Ontario N6C 2V5, Canada *Correspondence: [email protected] DOI 10.1016/j.stem.2010.03.014 SUMMARY 5a (TRIM5a), zinc finger antiviral protein (ZAP), TRIM19/PML (promyelocytic leukemia), and the TRIM28-ZFP809 (zinc finger To prevent insertional mutagenesis arising from antiviral protein 809) complex all restrict retroviral tropism via retroviral reactivation, cells of embryonic origin direct biochemical interactions (Best et al., 1996; Kaiser et al., possess a unique capacity to silence retroviruses. 2007; Gao et al., 2002; Turelli et al., 2001; Wolf and Goff, 2009; Given the distinct modes of X chromosome inactiva- Rowe et al., 2010). tion between embryonic and extraembryonic line- Less well understood is the process of retroviral extinction, ages, we investigated paradigms of viral extinction. which is progressive silencing of proviral transcription that occurs over long-term cellular growth or differentiation (Cherry We show that trophectoderm stem cells do not et al., 2000; Laker et al., 1998).
    [Show full text]
  • X-Inactivation in Female Human Embryonic Stem Cells Is in a Nonrandom Pattern and Prone to Epigenetic Alterations
    X-inactivation in female human embryonic stem cells is in a nonrandom pattern and prone to epigenetic alterations Yin Shen*, Youko Matsuno†, Shaun D. Fouse*, Nagesh Rao‡, Sierra Root§, Renhe Xu§, Matteo Pellegrini¶, Arthur D. Riggs†ʈ, and Guoping Fan*ʈ *Department of Human Genetics, Geffen School of Medicine, and Departments of ‡Pathology and Laboratory Medicine and ¶Molecular Cell and Developmental Biology, University of California, Los Angeles, CA 90095; †Division of Biology, Beckman Research Institute of the City of Hope, Duarte, CA 91010; and §Department of Genetics and Development, University of Connecticut Health Center, Farmington, CT 06032 Contributed by Arthur D. Riggs, December 21, 2007 (sent for review December 6, 2007) X chromosome inactivation (XCI) is an essential mechanism for dosage compensation of X-linked genes in female cells. We report that subcultures from lines of female human embryonic stem cells (hESCs) exhibit variation (0–100%) for XCI markers, including XIST RNA expression and enrichment of histone H3 lysine 27 trimethylation (H3K27me3) on the inactive X chromosome (Xi). Surprisingly, regard- less of the presence or absence of XCI markers in different cultures, all female hESCs we examined (H7, H9, and HSF6 cells) exhibit a monoallelic expression pattern for a majority of X-linked genes. Our results suggest that these established female hESCs have already completed XCI during the process of derivation and/or propagation, and the XCI pattern of lines we investigated is already not random. Moreover, XIST gene expression in subsets of cultured female hESCs is unstable and subject to stable epigenetic silencing by DNA meth- ylation. In the absence of XIST expression, Ϸ12% of X-linked pro- moter CpG islands become hypomethylated and a portion of X-linked alleles on the Xi are reactivated.
    [Show full text]
  • Epigenetic Modulation of the Tumor Immune Microenvironment to Potentiate Immune Checkpoint Blockade Therapy Johannes Menzel and Joshua C
    VIEWS IN THE SPOTLIGHT Epigenetic Modulation of the Tumor Immune Microenvironment to Potentiate Immune Checkpoint Blockade Therapy Johannes Menzel and Joshua C. Black Summary: Response rates to immune checkpoint blockade (ICB) in KRAS-mutant lung adenocarcinoma remain poor. In this issue of Cancer Discovery , Li and colleagues report an in vivo CRISPR screen of epigenetic regula- tors of the tumor immune microenvironment that uncovers Asf1a as a tumor-intrinsic suppressor of ICB through suppression of GM-CSF expression. See related article by Li et al., p. 270 (3). Lung adenocarcinoma is a leading cause of cancer-related would potentiate the effects of anti–PD-1 immunotherapy. death worldwide. Mutations in KRAS or EGFR are both Using this approach, the authors identifi ed that knockout major oncogenic drivers of lung cancer. Patients harboring (KO) of the histone H3-H4 chaperone Asf1a in the KP adeno- EGFR mutations can benefi t from EGFR tyrosine kinase carcinoma cells sensitizes the tumor to checkpoint blockade. inhibitors, but, despite the development of allele-specifi c Intriguingly, Asf1a knockout in the KP lung tumor cells KRAS G12C inhibitors, patients harboring KRAS mutations results in signifi cantly impaired tumor growth only when fail to benefi t from targeted inhibitors ( 1 ). The advance- treated with anti–PD-1. The combined Asf1a defi ciency and ment of immunotherapy is promising for treatment of anti–PD-1 treatment resulted in increased infl ammation, adenocarcinoma. Immune checkpoint blockade (ICB) thera- increased tumor-associated macrophages with M1-like polar- pies are now FDA-approved for the treatment of a broad ization, and increased T-cell infi ltration in the tumor.
    [Show full text]
  • Gene Section Review
    Atlas of Genetics and Cytogenetics in Oncology and Haematology INIST -CNRS OPEN ACCESS JOURNAL Gene Section Review HELLS (Helicase, Lymphoid-Specific) Kathrin Muegge, Theresa Geiman Laboratory of Cancer Prevention, SAIC-Frederick, National Cancer Institute, Frederick, Maryland 21701, USA (KM, TG) Published in Atlas Database: March 2014 Online updated version : http://AtlasGeneticsOncology.org/Genes/HELLSID40811ch10q23.html DOI: 10.4267/2042/54166 This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2014 Atlas of Genetics and Cytogenetics in Oncology and Haematology methylation and histone modifications alter cellular Abstract processes such as transcription, mitosis, meiosis, Review on HELLS, with data on DNA/RNA, on the and DNA repair. protein encoded and where the gene is implicated. HELLS has been shown to be important for stem cell gene control, Hox gene control, DNA Identity methylation, DNA repair, meiosis, and chromatin Other names: LSH, PASG, SMARCA6 packaging of repetitive DNA (Dennis et al., 2001; HGNC (Hugo): HELLS Yan et al., 2003b; De La Fuente et al., 2006; Myant et al., 2008; Burrage et al., 2012). Location: 10q23.33 HELLS belongs to the SNF2 family of chromatin Note remodelling proteins. HELLS (helicase, lymphoid specific) is a member This group of proteins are involved in altering of the SNF2 family of chromatin remodelling chromatin structure by hydrolyzing ATP and proteins that utilize ATP to alter the structure and moving nucleosomes. HELLS has orthologues in packaging of chromatin (Jarvis et al., 1996). These mouse, Xenopus laevis, Danio rerio, Arabidopsis changes in chromatin together with changes in thaliana, and Saccharomyces cerevisiae among other epigenetic mechanisms such as DNA others.
    [Show full text]